Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 375-376, 2007; 10.1373/clinchem.2006.084038
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Norden, A. G.W.
Right arrow Articles by Unwin, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Norden, A. G.W.
Right arrow Articles by Unwin, R. J.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2007;53:375-376.)
© 2007 American Association for Clinical Chemistry, Inc.

Editorial

Clinical Urinary Peptidomics: Learning to Walk Before We Can Run

Anthony G.W. Norden1,a, Pedro Rodriguez-Cutillas2 and Robert J. Unwin3

1 Department of Clinical Biochemistry, Cambridge University Teaching Hospitals, Addenbrooke"s Hospital, Cambridge, United Kingdom
2 Ludwig Institute for Cancer Research, and Department of Biochemistry and Molecular Biology, University College, London, United Kingdom
3 Centre for Nephrology and Department of Physiology, Royal Free and University, College Medical School, London, United Kingdom

aAddress correspondence to this author at: Box 232, Hills Road, Cambridge CB2 2QR, United Kingdom. E-mail agwn2@cam.ac.uk.

The first 20% of the full text of this article appears below.

The "urinary peptidome" promises to be a resource at least as dynamic and informative as the "urinary proteome". Given that neither approach has so far given up many clinical pearls, this may not be saying much. But one likely pathway for urinary peptidomics is set out in the paper by Fiedler et al. (1) in this issue of Clinical Chemistry. These workers have combined high-throughput technology with a study of the basic problems that will need to be overcome to transform a promising approach into something more durable. Although they are not the first to use some of the techniques (2)(3), and although numerous problems remain, this study is required reading for all those interested in this area.

Urine, as a matrix, must be one of the least desirable biological fluids for both peptidomic and proteomic work. It is important to recall some basic biology: The composition of urine is by its design highly variable. Indeed the variability of its composition is a major way in which the "milieu interieur" is kept more or less constant in the face of environmental and nutritional changes. Urine volume, salt composition and pH can, and do, vary widely in health. In disease there is frequently proteinuria and, if that were not enough, urine is often infected even in apparently healthy individuals. Having said that, urine is also the source of one of . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Mol. Cell. ProteomicsHome page
L. F. Quintana, J. M. Campistol, M. P. Alcolea, E. Banon-Maneus, A. Sol-Gonzalez, and P. R. Cutillas
Application of Label-free Quantitative Peptidomics for the Identification of Urinary Biomarkers of Kidney Chronic Allograft Dysfunction
Mol. Cell. Proteomics, July 1, 2009; 8(7): 1658 - 1673.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.